Sugi Predict

Sugi Predict / Compounds / SCHEMBL1498779

SCHEMBL1498779

SCHEMBL1498779

COC(=O)c1ccc(C(F)F)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.43
▸ CA1 P00915 2/20 0.43
▸ CA2 P00918 2/20 0.43
▸ CA7 P43166 2/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ CA14 Q9ULX7 2/20 0.43
▸ PDK2 Q15119 1/20 0.43
▸ PDK4 Q16654 1/20 0.43
▸ ALDH1A1 P00352 5/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ MET P08581 1/20 0.42
▸ GAA P10253 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ CASP7 P55210 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ CFTR P13569 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7220810 0.90 MAPT (0.47) CA12CA1CA2CA7CA9
SCHEMBL31455721 0.88 CA12 (0.42) CA12CA1CA2CA7CA9
SCHEMBL16959892 0.87 CA12 (0.41) CA12CA1CA2CA7CA9
SCHEMBL31455899 0.87 CA12 (0.41) CA12CA1CA2CA7CA9
SCHEMBL17524485 0.87 DPP4 (0.45) CA12CA1CA2CA7CA9
SCHEMBL18758435 0.87 DPP4 (0.45) CA12CA1CA2CA7CA9
SCHEMBL29893863 0.87 DPP4 (0.45) CA12CA1CA2CA7CA9
SCHEMBL16398002 0.86 ALDH1A1 (0.43) CA12CA1CA2CA7CA9
Hydrochloric Acid SCHEMBL29894217 0.85 DPP4 (0.44) CA12CA1CA2CA7CA9
Hydrochloric Acid SCHEMBL16097548 0.85 DPP4 (0.44) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570642-B2 GLP-IR modulating compounds GILEAD SCIENCES, INC. (US) 2026-03-10 — — US disclosed
EP-4691554-A2 GLP-1R MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2026-02-11 — — EP disclosed
EP-4271672-B1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-12-03 — — EP disclosed
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) 2025-04-03 — — US disclosed
CN-116003309-B Hydrazide compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2025-03-04 — — CN disclosed
CN-119343339-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2025-01-21 — — CN disclosed
EP-4469444-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2024-12-04 — — EP disclosed
US-20240199589-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-20 — — US disclosed
US-11858918-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2024-01-02 — — US disclosed
US-11858918-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2024-01-02 — — US disclosed
US-20190031628-A1 AMINOAZOLE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2019-01-31 — — US disclosed
EP-3388425-A1 AMINOAZOLE DERIVATIVE Teijin Pharma Limited (JP) 2018-10-17 — — EP disclosed
WO-2017090743-A1 NOVEL IMIDAZOLE COMPOUND AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONIST 田辺三菱製薬株式会社 2017-06-01 — — WO disclosed
US-9249145-B2 Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2016-02-02 — — US disclosed
US-9249145-B2 Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2016-02-02 — — US disclosed
US-9249145-B2 Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2016-02-02 — — US disclosed
WO-2011028685-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2011-03-10 — — WO disclosed
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2011-03-10 — — US disclosed
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2011-03-10 — — US disclosed
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2011-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR CA12 4343/4885CA1 4270/4885CA2 3688/4885
US-20190031628-A1 AMINOAZOLE DERIVATIVE AR, NR3C2, NR5A1 CA12 715/4885CA1 1484/4885CA2 1404/4885
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 CA12 4774/4885CA1 4663/4885CA2 4295/4885
US-11858918-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 CA12 4646/4885CA1 4287/4885CA2 3698/4885
US-20240199589-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 CA12 4646/4885CA1 4287/4885CA2 3698/4885
US-12570642-B2 GLP-IR modulating compounds GLP1R, GIPR, GPR119 CA12 2715/4885CA1 2821/4885CA2 1193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.